298 related articles for article (PubMed ID: 16917844)
21. Formation of reactive impurities in aqueous and neat polyethylene glycol 400 and effects of antioxidants and oxidation inducers.
Hemenway JN; Carvalho TC; Rao VM; Wu Y; Levons JK; Narang AS; Paruchuri SR; Stamato HJ; Varia SA
J Pharm Sci; 2012 Sep; 101(9):3305-18. PubMed ID: 22610374
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of hydroxypropyl methylcellulose matrix systems as swellable gastro-retentive drug delivery systems (GRDDS).
Matharu AS; Motto MG; Patel MR; Simonelli AP; Dave RH
J Pharm Sci; 2011 Jan; 100(1):150-63. PubMed ID: 20572054
[TBL] [Abstract][Full Text] [Related]
23. A study of micronized poloxamers as lubricants in direct compression of tablets.
Muzíková J; Vyhlídalová B; Pekárek T
Acta Pol Pharm; 2013; 70(6):1087-96. PubMed ID: 24383332
[TBL] [Abstract][Full Text] [Related]
24. Continuous and scalable process for water-redispersible nanoformulation of poorly aqueous soluble APIs by antisolvent precipitation and spray-drying.
Hu J; Ng WK; Dong Y; Shen S; Tan RB
Int J Pharm; 2011 Feb; 404(1-2):198-204. PubMed ID: 21056643
[TBL] [Abstract][Full Text] [Related]
25. The effect of polymeric additives on the solubilisation of a poorly-soluble drug in micellar solutions of Pluronic F127.
Oliveira CP; Vasconcellos LC; Ribeiro ME; Ricardo NM; Souza TV; Costa Fde M; Chaibundit C; Yeates SG; Attwood D
Int J Pharm; 2011 May; 409(1-2):206-8. PubMed ID: 21354466
[TBL] [Abstract][Full Text] [Related]
26. Biopharmaceutical aspects and implications of excipient variability in drug product performance.
Zarmpi P; Flanagan T; Meehan E; Mann J; Fotaki N
Eur J Pharm Biopharm; 2017 Feb; 111():1-15. PubMed ID: 27845182
[TBL] [Abstract][Full Text] [Related]
27. Production of pellets via extrusion-spheronisation without the incorporation of microcrystalline cellulose: a critical review.
Dukić-Ott A; Thommes M; Remon JP; Kleinebudde P; Vervaet C
Eur J Pharm Biopharm; 2009 Jan; 71(1):38-46. PubMed ID: 18771727
[TBL] [Abstract][Full Text] [Related]
28. The Effects of Fillers and Binders on the Accuracy of Tablet Subdivision.
Pereira GRS; Taveira SF; Cunha-Filho M; Marreto RN
AAPS PharmSciTech; 2018 Oct; 19(7):2929-2933. PubMed ID: 30120694
[TBL] [Abstract][Full Text] [Related]
29. Impact Of Excipient Variability On Drug Product Processing And Performance.
Peng Soh JL; Liew CV; Sia Heng PW
Curr Pharm Des; 2015; 21(40):5890-9. PubMed ID: 26446469
[TBL] [Abstract][Full Text] [Related]
30. Preparation and evaluation of high dispersion stable nanocrystal formulation of poorly water-soluble compounds by using povacoat.
Yuminoki K; Seko F; Horii S; Takeuchi H; Teramoto K; Nakada Y; Hashimoto N
J Pharm Sci; 2014 Nov; 103(11):3772-3781. PubMed ID: 25209659
[TBL] [Abstract][Full Text] [Related]
31. The influence of formulation excipients on the stability of the novel antitumor agent carzelesin (U-80,244).
Jonkman-De Vries JD; Rosing H; Henrar RE; Bult A; Beijnen JH
PDA J Pharm Sci Technol; 1995; 49(6):283-8. PubMed ID: 8581459
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive Insight into Chemical Stability of Important Antidiabetic Drug Vildagliptin Using Chromatography (LC-UV and UHPLC-DAD-MS) and Spectroscopy (Mid-IR and NIR with PCA).
Gumieniczek A; Berecka-Rycerz A; Fornal E; Żyżyńska-Granica B; Granica S
Molecules; 2021 Sep; 26(18):. PubMed ID: 34577104
[TBL] [Abstract][Full Text] [Related]
33. Computational prediction of drug solubility in lipid based formulation excipients.
Persson LC; Porter CJ; Charman WN; Bergström CA
Pharm Res; 2013 Dec; 30(12):3225-37. PubMed ID: 23771564
[TBL] [Abstract][Full Text] [Related]
34. Solid dispersion of meloxicam: factorially designed dosage form for geriatric population.
Pathak D; Dahiya S; Pathak K
Acta Pharm; 2008 Mar; 58(1):99-110. PubMed ID: 18337211
[TBL] [Abstract][Full Text] [Related]
35. Development of an osmotic pump system for controlled delivery of diclofenac sodium.
Emara LH; Taha NF; Badr RM; Mursi NM
Drug Discov Ther; 2012 Oct; 6(5):269-77. PubMed ID: 23229148
[TBL] [Abstract][Full Text] [Related]
36. Solubilizing excipients in oral and injectable formulations.
Strickley RG
Pharm Res; 2004 Feb; 21(2):201-30. PubMed ID: 15032302
[TBL] [Abstract][Full Text] [Related]
37. Practical considerations in development of solid dosage forms that contain cyclodextrin.
Miller LA; Carrier RL; Ahmed I
J Pharm Sci; 2007 Jul; 96(7):1691-707. PubMed ID: 17243148
[TBL] [Abstract][Full Text] [Related]
38. II. Technological approaches to improve the dissolution behavior of nateglinide, a lipophilic insoluble drug: co-milling.
Maggi L; Bruni G; Maietta M; Canobbio A; Cardini A; Conte U
Int J Pharm; 2013 Sep; 454(1):568-72. PubMed ID: 23872227
[TBL] [Abstract][Full Text] [Related]
39. Hot melt extruded transdermal films based on amorphous solid dispersions in Eudragit RS PO: The inclusion of hydrophilic additives to develop moisture-activated release systems.
Albarahmieh E; Qi S; Craig DQM
Int J Pharm; 2016 Nov; 514(1):270-281. PubMed ID: 27863672
[TBL] [Abstract][Full Text] [Related]
40. Effect of drug solubility and different excipients on floating behaviour and release from glyceryl monooleate matrices.
Kumar M K; Shah MH; Ketkar A; Mahadik KR; Paradkar A
Int J Pharm; 2004 Mar; 272(1-2):151-60. PubMed ID: 15019078
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
